7 unknown. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 7 |
Follow icotinib: new trials by email Literature Review of icotinib trials Research Report on icotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC Anlotinib, Icotinib - Non Small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 206 | 2021-03-12 | 2021-03-15 |
| Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. Icotinib - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 70 | 2019-07-01 | 2019-06-20 |
| A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy Icotinib, SRS/WBRT/HA-WBRT/SMART - Non Small Cell Lung Cancer, Brain Metastases | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 296 | 2018-07-20 | 2019-08-15 |
| First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation icotinib, Chemotherapy, Radiotherapy - Non-small Cell Lung Cancer | Phase 3 | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 330 | 2016-06-01 | 2016-08-30 |
| Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation Icotinib, Chemotherapy - Non-small Cell Lung Cancer | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 320 | 2015-06-08 | 2021-07-20 |
| Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib, WBRT, HFSRS - Stage IV EGFR Mutated NSCL With Brain Metastases | Phase 3 | Unknown | Sichuan Provincial People's Hospital | 325 | 2015-03-01 | 2016-08-30 |
| Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Icotinib, Placebo - EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 124 | 2014-09-01 | 2018-07-16 |
Carcinoma, Non-Small-Cell Lung (4) · Adenocarcinoma (1) · Brain Neoplasms (1)
Betta Pharmaceuticals Co., Ltd. (3) · Tianjin Medical University Cancer Institute and Hospital (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Sichuan Provincial People's Hospital (1)
China (6)
Caicun Zhou, MD (1) · Chen Ming (1) · Jianxing He, MD (1) · Ming Zeng, MD PhD (1) · Peng Chen, M.D. (1) · Yuan-Kai Shi, MD (1) · Zhenzhou Yang, MD (1)
PMID 22967997, PMID 27619516, PMID 32606956, PMID 34280355, PMID 40421698, PMID 42660909